Avicanna Subsidiary SMGH Exports Aureus Branded CBD and CBG Into Paraguay
July 17 2023 - 7:30AM
Avicanna Inc. (“
Avicanna” or the
“
Company) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) a
biopharmaceutical company focused on the development, manufacturing
and commercialisation of plant-derived cannabinoid-based products
is pleased to announce that through its majority owned subsididery
Santa Marta Golden Hemp the Company has completed the commercial
export of aureus branded products into Paraguay.
The commercial export included Aureus branded
purified Cannabidiol (CBD) and Cannabigerol (CBG) which is a part
of the company’s portfolio of cannabinoid active pharmaceutical
ingredients). This transaction also marks the 17th international
market for Aureus branded products and 20th market for all Avicanna
products which further demonstrates the company’s capabilities in
navigating complex regulatory processes for its commercialization
efforts internationally.
About Aureus™
Avicanna’s supply chain business unit is based
in Santa Marta, Colombia and provides a consistent source of
cannabinoid raw materials for the global marketplace with GACP and
USDA organic ceritications. These include active pharmaceutical
ingredients and feminized seeds, for Avicanna’s cosmetic, medical,
and pharmaceutical products, in addition to supplying the company’s
partners around the world.
Aureus-branded products are cultivated,
extracted, and manufactured by Avicanna’s subsidiaries in Colombia
where they leverage optimal environmental conditions to produce
cannabinoid active pharmaceutical ingredients economically and
sustainably and include a range of extracts of CBD, THC and rare
cannabinoids such as CBG.
To its knowledge, the Company carries out its
operations in compliance with all applicable laws in the
jurisdictions in which it operates.
About Avicanna Inc.
Avicanna is a commercial-stage international
biopharmaceutical company focused on the advancement and
commercialization of evidence-based cannabinoid-based products for
the global medical and pharmaceutical market segments. Avicanna has
an established scientific platform including R&D and clinical
development that has led to the commercialization of more than
thirty products across various market segments:
- Medical Cannabis &
Wellness Products (RHO Phyto™): The formulary offers
a diverse range of proprietary formulations including oral,
sublingual, topical, and transdermal deliveries with varying ratios
of cannabinoids and is supported with ongoing patient, and medical
community education. RHO Phyto has been established as a leading
medical brand in Canada and is currently available nationwide to
patients across several medical channels and continues to expand
into new international markets.
- Pharmaceutical Preparations
and Pipeline: Leveraging Avicanna’s
scientific platform, vertical integration, and real-world evidence,
Avicanna has developed an extensive a pipeline of patent-pending
drug candidates that are indication-specific and in various stages
of clinical development and commercialization. These
cannabinoid-based drug candidates look to address unmet medical
needs in the areas of dermatology, chronic pain, and various
neurological disorders. Avicanna’s first pharmaceutical preparation
(Trunerox™) is in the drug registration stage in South
America.
- MyMedi.ca Medical Cannabis
Care Portal: MyMedi.ca is Avicanna’s medical cannabis care
platform that is formed with the aim to better serve medical
cannabis patients’ needs and enhance the patient journey. MyMedi.ca
is expected to launch during August 2023 and will feature diverse
and scientifically curated products from leading Canadian licensed
producers in addition to pharmacist led patient support programs
and educational resources to facilitate the incorporation of
medical cannabis into health care regimens. MyMedi.ca also provides
specialty services to distinct patient groups such as veterans and
collaborating with public and private providers for adjudication
and reimbursement.
Click to watch Avicanna’s Corporate Video 2022
SOURCE Avicanna Inc.
Stay Connected
For more information about Avicanna, visit our
website, contact Ivana Maric by email at info@avicanna.com or
follow us on social media
on LinkedIn, Twitter, Facebook, or Instagram.
The Company posts updates through videos from
the Company YouTube channel.
Cautionary Note Regarding Forward-Looking Information
and Statements
This news release contains “forward-looking
information” within the meaning of applicable securities laws.
Forward-looking information contained in this news release may be
identified using words such as, “may”, “would”, “could”, “will”,
“likely”, “expect”, “anticipate”, “believe, “intend”, “plan”,
“forecast”, “project”, “estimate”, “outlook” and other similar
expressions. Although the Company believes that the expectations
and assumptions on which such forward looking information is based
are reasonable, undue reliance should not be placed on the
forward-looking information because the Company can give no
assurance that they will prove to be correct. Actual results and
developments may differ materially from those contemplated by these
statements. Forward-looking information is subject to a variety of
risks and uncertainties that could cause actual events or results
to differ materially from those projected in the forward-looking
information. Such risks and uncertainties include but are not
limited to current and future market conditions, including the
market price of the common shares of the Company, and the risk
factors set out in the Company’s annual information form dated
March 31, 2023 filed with the Canadian securities regulators and
available under the Company’s profile on SEDAR at www.sedar.com.
The statements in this news release are made as of the date of this
release. The Company disclaims any intent or obligation to update
any forward-looking information, whether as a result of new
information, future events or results or otherwise, other than as
required by applicable securities laws.
A photo accompanying this announcement is available at
https://www.globenewswire.com/NewsRoom/AttachmentNg/f28e7282-ef7e-4002-8da7-c61b15887c11
Avicanna (TSX:AVCN)
Historical Stock Chart
From Apr 2024 to May 2024
Avicanna (TSX:AVCN)
Historical Stock Chart
From May 2023 to May 2024